Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2025
PHARMAC to fund more cancer medicines (March 2025)
12 March 2025 - PHARMAC is funding six more medicines for cancers and one for antibiotic resistant infections. ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 12 Mar 2025
Natalizumab for the treatment of patients with highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
12 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 11 Mar 2025
PHARMAC funds new oral contraceptive pill
11 March 2025 - PHARMAC has decided to fund a new progestogen only oral contraceptive pill called desogestrel (Cerazette). ...
Posted by Michael Wonder on 10 Mar 2025
SMC - March 2025 decisions
10 March 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 10 Mar 2025
New insulin medicine proposed for people with diabetes
10 March 2025 - PHARMAC is seeking public feedback on a proposal to fund a new, additional type of insulin ...
Posted by Michael Wonder on 10 Mar 2025
Life changing new drug available for elderly Australians with devastating eye condition
9 March 2025 - A life changing new drug is now available on the PBS for elderly Australians with a ...
Posted by Michael Wonder on 08 Mar 2025
This immunotherapy drug helped me beat cancer - instead of $229k it now costs $31
8 March 2025 - When she was just 26-years-old, Bianca Tesoriero’s life changed in an instant, following a visit to her ...
Posted by Michael Wonder on 07 Mar 2025
Public Summary Documents – November 2024 PBAC meeting
7 March 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2024 PBAC ...
Posted by Michael Wonder on 07 Mar 2025
Amivantamab in combination with pemetrexed disodium heptahydrate and carboplatin for the treatment of patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer
6 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 07 Mar 2025
Second consultation launched on NHS funding for Alzheimer's treatments
6 March 2025 - Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. ...
Posted by Michael Wonder on 06 Mar 2025
Cemiplimab in combination with platinum-based chemotherapy for the treatment of patients with advanced non-small-cell lung cancer
5 March 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 06 Mar 2025
Idebenone for the treatment of patients 12 years of age and older with visual impairment in Leber’s hereditary optic neuropathy (updated draft guidance)
5 March 2025 - NICE has produced additional draft guidance on the use of idebenone in the NHS in England. ...
Posted by Michael Wonder on 05 Mar 2025
Sparsentan for the treatment of patients with primary IgA nephropathy
4 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...